TB Alliance regimen development for multidrug-resistant tuberculosis

被引：23
作者：
Murray, S. [1 ]
Mendel, C. [1 ]
Spigelman, M. [1 ]
机构：
[1] Global Alliance TB Drug Dev TB Alliance, 24th Floor,40 Wall St, New York, NY 10005 USA
来源：
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2016年 / 20卷 / 12期
关键词：
bedaquiline; clinical trial; moxifloxacin; oxazolidinone; pretomanid; pyrazinamide; tuberculosis; PYRAZINAMIDE; MOXIFLOXACIN; COMBINATION; OUTCOMES; PA-824;
D O I：
10.5588/ijtld.16.0069
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The recent approval of new tuberculosis (TB) drugs raises hope for new and more effective anti-tuberculosis treatment regimens. The Global Alliance for TB Drug Development (TB Alliance) is committed to ensuring that new anti-tuberculosis drugs fulfill the needs of patients, their families and the local health services that serve the communities. Here we present highlights of the TB Alliance's pipeline of regimen development, with novel regimens for patients with drug-susceptible, multidrug-resistant and extensively drug-resistant TB. The ongoing clinical trials (STAND, NC-005, Nix-TB and LIN-CL001) are outlined and their rationale and goals presented.
引用
收藏
页码：S38 / S41
页数：4
相关论文
共 12 条
  • [1] [Anonymous], GLOB TUB REP
  • [2] Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
    Dawson, Rodney
    Diacon, Andreas H.
    Everitt, Daniel
    van Niekerk, Christo
    Donald, Peter R.
    Burger, Divan A.
    Schall, Robert
    Spigelman, Melvin
    Conradie, Almari
    Eisenach, Kathleen
    Venter, Amour
    Ive, Prudence
    Page-Shipp, Liesl
    Variava, Ebrahim
    Reither, Klaus
    Ntinginya, Nyanda E.
    Pym, Alexander
    von Groote-Bidlingmaier, Florian
    Mendel, Carl M.
    [J]. LANCET, 2015, 385 (9979) : 1738 - 1747
  • [3] PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis
    Dawson, Rodney
    Diacon, Andreas
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (07) : 927 - 932
  • [4] New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
    Leibert, Eric
    Danckers, Mauricio
    Rom, William N.
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 597 - 602
  • [5] Molecular Diagnosis of Tuberculosis and Drug Resistance
    Lin, Shou-Yean Grace
    Desmond, Edward P.
    [J]. CLINICS IN LABORATORY MEDICINE, 2014, 34 (02) : 297 - +
  • [6] Mdluli K., 2015, COLD SPRING HARB PER, V5
  • [7] Novel drugs against tuberculosis: a clinician's perspective
    Olaru, Ioana Diana
    von Groote-Bidlingmaier, Florian
    Heyckendorf, Jan
    Yew, Wing Wai
    Lange, Christoph
    Chang, Kwok Chiu
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (04) : 1119 - 1131
  • [8] Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study
    Pietersen, Elize
    Ignatius, Elisa
    Streicher, Elizabeth M.
    Mastrapa, Barbara
    Padanilam, Xavier
    Pooran, Anil
    Badri, Motasim
    Lesosky, Maia
    van Helden, Paul
    Sirgel, Frederick A.
    Warren, Robin
    Dheda, Keertan
    [J]. LANCET, 2014, 383 (9924) : 1230 - 1239
  • [9] Delamanid: First Global Approval
    Ryan, Nicola J.
    Lo, Jin Han
    [J]. DRUGS, 2014, 74 (09) : 1041 - 1045
  • [10] Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
    Skripconoka, Vija
    Danilovits, Manfred
    Pehme, Lea
    Tomsonl, Tarmo
    Skenders, Girts
    Kummile, Tiina
    Cirule, Andra
    Leimane, Vaira
    Kurvell, Anu
    Levinalr, Klavdia
    Geiter, Lawrence J.
    Manisser, Davide
    Wells, Charles D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (06) : 1393 - 1400
12